Get started
Author

Srikumar Sahasranaman

Observed names: S Sahasranaman, S. Sahasranaman, Sahasranaman Srikumar, Sahasranaman, Srikumar
Observed institutions: University of Nottingham, National University of Singapore, University of California, San Francisco, Genentech, Nottingham City Hospital, University of Florida, Sanofi (United States), Novartis (United States), BeOne Medicines (Switzerland)
ORCID: 0000-0002-0762-2967
Observed ORCID: 0000-0002-0762-2967
OpenAlex ID: A5043786963
Clinical pharmacology and pharmacogenetics of thiopurines
2008 · Srikumar Sahasranaman, Danny Howard, et al. · European Journal of Clinical Pharmacology · 415
A phase 2 study of the BH3 mimetic BCL2 inhibitor navitoclax (ABT-263) with or without rituximab, in previously untreated B-cell chronic lymphocytic leukemia
2015 · Thomas J. Kipps, Herbert Eradat, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 205
Immune Checkpoint inhibitors: An introduction to the next‐generation cancer immunotherapy
2015 · Lucy Lee, Manish Gupta, et al. · The Journal of Clinical Pharmacology · 156
PDF
The acute antiparkinsonian and antidyskinetic effect of AFQ056, a novel metabotropic glutamate receptor type 5 antagonist, in l-Dopa-treated parkinsonian monkeys
2011 · Laurent Grégoire, Nicolas Morin, et al. · Parkinsonism & Related Disorders · 112
Targeting TIGIT for Immunotherapy of Cancer: Update on Clinical Development
2021 · Anand Rotte, Srikumar Sahasranaman, et al. · Biomedicines · 79
PDF
Phase I Study of GDC-0425, a Checkpoint Kinase 1 Inhibitor, in Combination with Gemcitabine in Patients with Refractory Solid Tumors
2016 · Jeffrey R. Infante, Antoine Hollebecque, et al. · Clinical Cancer Research · 71
Plasma concentrations of inhaled corticosteroids in relation to airflow obstruction in asthma
2006 · Kevin J. Mortimer, Tim W. Harrison, et al. · British Journal of Clinical Pharmacology · 52
PDF
Model-Based Covariate Pharmacokinetic Analysis and Lack of Cortisol Suppression by the New Inhaled Corticosteroid Ciclesonide Using a Novel Cortisol Release Model
2005 · Shashank Rohatagi, Sriram Krishnaswami, et al. · American Journal of Therapeutics · 45
Effect of rifampin and itraconazole on the pharmacokinetics of zanubrutinib (a Bruton's tyrosine kinase inhibitor) in Asian and non-Asian healthy subjects
2019 · Song Mu, Zhiyu Tang, et al. · Cancer Chemotherapy and Pharmacology · 41
PDF
Differences in the glucocorticoid to progesterone receptor selectivity of inhaled glucocorticoids
2006 · M. Issar, S. Sahasranaman, et al. · European Respiratory Journal · 41
PDF
Effect of OATP1B1/1B3 Inhibitor GDC‐0810 on the Pharmacokinetics of Pravastatin and Coproporphyrin I/III in Healthy Female Subjects
2018 · Lichuan Liu, Sravanthi Cheeti, et al. · The Journal of Clinical Pharmacology · 37
GDC-0810 Pharmacokinetics and Transporter-Mediated Drug Interaction Evaluation with an Endogenous Biomarker in the First-in-Human, Dose Escalation Study
2019 · Kit Wun Kathy Cheung, Kenta Yoshida, et al. · Drug Metabolism and Disposition · 35
PDF
Rationale for once-daily or twice-daily dosing of zanubrutinib in patients with mantle cell lymphoma
2021 · Ying C. Ou, Zhiyu Tang, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 32
Comprehensive PBPK model to predict drug interaction potential of Zanubrutinib as a victim or perpetrator
2021 · Kun Wang, Xueting Yao, et al. · CPT Pharmacometrics & Systems Pharmacology · 32
PDF
Population Pharmacokinetic Analysis of the BTK Inhibitor Zanubrutinib in Healthy Volunteers and Patients With B‐Cell Malignancies
2020 · Ying C. Ou, Lucy Liu, et al. · Clinical and Translational Science · 29
PDF
Metabolism of Mometasone Furoate and Biological Activity of the Metabolites
2005 · S. Sahasranaman, M. Issar, et al. · Drug Metabolism and Disposition · 25
Evaluation of drug interaction potential of zanubrutinib with cocktail probes representative of CYP3A4, CYP2C9, CYP2C19, P‐gp and BCRP
2020 · Ying C. Ou, Zhiyu Tang, et al. · British Journal of Clinical Pharmacology · 22
PDF
Strategies to Address Drug Interaction Potential for Antibody–Drug Conjugates in Clinical Development
2013 · Dan Lu, Srikumar Sahasranaman, et al. · Bioanalysis · 22
A phase 1, open-label, single-dose study of the pharmacokinetics of zanubrutinib in subjects with varying degrees of hepatic impairment
2020 · Ying C. Ou, Richard A. Preston, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 21
A sensitive liquid chromatography–tandem mass spectrometry method for the quantification of mometasone furoate in human plasma
2005 · Srikumar Sahasranaman, Yufei Tang, et al. · Journal of Chromatography B · 21
Evaluation of HDL-modulating interventions for cardiovascular risk reduction using a systems pharmacology approach
2015 · Kapil Gadkar, James Lu, et al. · Journal of Lipid Research · 20
Model‐based population pharmacokinetic analysis of tislelizumab in patients with advanced tumors
2022 · Nageshwar Budha, Chi‐Yuan Wu, et al. · CPT Pharmacometrics & Systems Pharmacology · 19
PDF
Assessment of OATP transporter‐mediated drug–drug interaction using physiologically‐based pharmacokinetic (PBPK) modeling – a case example
2018 · Yuan Chen, Rui Zhu, et al. · Biopharmaceutics & Drug Disposition · 15
In vitro investigations into the roles of CYP450 enzymes and drug transporters in the drug interactions of zanubrutinib, a covalent Bruton's tyrosine kinase inhibitor
2021 · Heather Zhang, Ying C. Ou, et al. · Pharmacology Research & Perspectives · 14
Use of in Vitro Critical Inhibitory Concentration, a Novel Approach to Predict in Vivo Synergistic Bactericidal Effect of Combined Amikacin and Piperacillin Against Pseudomonas aeruginosa in a Systemic Rat Infection Model
2006 · Eli Chan, Shufeng Zhou, et al. · Pharmaceutical Research · 14
Works count: 56
Citation count: 1,698
H-index: 20
I10-index: 30
Year
Topic
Type